Results 221 to 230 of about 43,472 (345)

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract Intestinal failure‐associated liver disease occurs in 20% to 30% of patients with short bowel syndrome and intestinal failure (SBS‐IF). Apraglutide is a glucagon‐like peptide‐2 (GLP‐2) analog in clinical development for the treatment of patients with SBS‐IF.
Gerard Greig   +4 more
wiley   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

open access: yesClinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li   +4 more
wiley   +1 more source

Bile metabolite palmitic acid augments the migration of gallbladder cancer cells through the ROS/NF-кB signaling pathway. [PDF]

open access: yesSci Rep
Da X   +11 more
europepmc   +1 more source

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 1, January 2026.
Integrated framework for tirzepatide in HFpEF management. Through metabolic, haemodynamic, structural and anti‐inflammatory pathways, tirzepatide modifies the disease trajectory of HFpEF, leading to improvements in symptoms, functional capacity and reduction in HF events.
Hamza A. Abdul‐Hafez   +9 more
wiley   +1 more source

Identification of Cumulative Assessment Groups of Pesticides [PDF]

open access: yes, 2012
Boberg, Julie   +8 more
core   +1 more source

Comprehensive Review on the Occurrence of Aflatoxin M1 in Milk, Prevalent Health Issues Associated With It, and Innovative Strategies for Mitigation of Aflatoxin M1 in Processed Milk

open access: yesFood Safety and Health, Volume 4, Issue 1, Page 67-81, January 2026.
Aflatoxins, carcinogenic compounds in milk; reduction strategies such as thermal deactivation, UV light exposure, ionizing radiation, and solvent extraction. ABSTRACT Aflatoxins (AFs) are known to be cancer causing substances recognized within milk along with the milk goods.
Akshay Ramani   +6 more
wiley   +1 more source

Biological Activities, Health Benefits and Synthesis of Equol and Its Derivatives: A Comprehensive Review

open access: yesFood Science &Nutrition, Volume 14, Issue 1, January 2026.
Biological activities, health benefits and structures of equol and its derivatives. ABSTRACT Equol is a metabolite transformed from daidzein by intestinal microorganisms and has received extensive attention due to its various pharmacological activities and therapeutic potential.
Jiao‐Jiao Zhuo   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy